27 February 2017
Interim Report and Half-Yearly Financial Results
Starpharma released its interim report and financial results for the half-year ended 31 December 2016.
- Reported loss of $9.0M (Dec 2015: $10.0M)
- R&D tax incentives of $1.7M reported in the half-year (Dec 2015: $1.8M)
- Cash position at 31 December 2016 of $36.3M (June 2016: $46.0M)
- Receipt of $3.5M R&D tax incentive refund from FY16